Last reviewed · How we verify
NCT01969968: POLOB
Lipophilic Organic Polluants and Morbid Obesity
NA trial testing Lipophilic Organic Polluants dosage in Obesity in 232 participants. Completed in 19 September 2017.
19 September 2017
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire de Nice |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 232 |
| Start date | 18 December 2013 |
| Primary completion | 19 September 2017 |
| Estimated completion | 19 September 2017 |
| Sites | 1 location across France |
Drugs / interventions tested
- Lipophilic Organic Polluants dosage
Conditions studied
- Obesity — all drugs for Obesity →
Sponsor
Centre Hospitalier Universitaire de Nice
Who can join
Adults 18 to 65, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
1. To study the kinetics of release after bariatric surgery of selected polluants stored in adipose tissue, looking for clinical and/or predictive factors 2. To test the hypothesis of a deleterious effect of this release on the expected improvement of insulin-resistance and on the liver inflammation. 3. To determine the level of contamination of morbidly obese patients, with or without metabolic syndrome, compared to a control, non obese population, with special attention to clinical (age, gender, reproductive history, pregnancy, nursing) and biological parameters (insulin-resistance, inflammation).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01969968
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Centre Hospitalier Universitaire de Nice trials
Trials by the same sponsor.
- NCT05897996 — Percutaneous Anastomosis Creation for Hemodialysis Access · NA · withdrawn
- NCT07499869 — INNOVATIVE BENEFITS OF A 4D VIRTUAL SIMULATOR · NA · not yet recruiting
- NCT07492251 — Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Ran · Phase 2 · not yet recruiting
- NCT07511608 — Development of a New Technique for Quantifying Mitochondrial DNA in Single Muscle Fibers · NA · not yet recruiting
- NCT07582406 — Codesign, Physical Activity, and Seniors · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01969968 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nice
- Last refreshed: 18 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01969968.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing